Table 6.
Examples of ongoing or programmed clinical trials using different types of nanosystems for melanoma treatment.
| Nanosystem | Main Clinical Trial Description | Melanoma Stage | Sponsor | Estimated Starting or Completion Date | Trial ID |
|---|---|---|---|---|---|
| Liposomes | Safety and tolerability of a liposomal tetravalent RNA-drug products vaccine (Phase 1). | IIIB/C/IV | BioNTech SE | 2015–2023 | NCT02410733 |
| Safety and feasibility of a tumor mRNA-loaded liposomal vaccine (Phase 1). | IIB-IV | University of Florida | 2022–2027 | NCT05264974 | |
| Lipid nanoparticles | Safety and efficacy of a lipid nanoparticle encapsulating mRNAs encoding a human T-cell co-stimulator and pro-inflammatory cytokines as monotherapy or in combination with durvalumab (Phase 1). | Advanced or metastatic | ModernaTX, Inc. | 2018–2023 | NCT03739931 |
| Polymeric nanoparticles | Safety and efficacy of the combination of nanoparticle albumin-bound paclitaxel with bevacizumab (Phase 1). | IV | Mayo Clinic | 2014–2025 | NCT02020707 |
| Comparison of the safety and efficacy of the combination of nanoparticle albumin-bound paclitaxel and carboplatin with and without endostatin (Phase 2). | Advanced | Peking University Cancer Hospital & Institute | 2019–2022 | NCT03917069 |
Data collected from the ClinicalTrials.gov database [126].